Evidence map›Paper›PMID 40022129›Full record

ArticleJournal of translational medicine2025

RPL22L1 fosters malignant features of cervical cancer via the modulation of DUSP6-ERK axis.

Dongmei Zhang, Meiqi Zhao, Ping Jiang, Yunzhen Zhou, Xu Yan, Chong Zhou, Yu Mu, Shan Xiao, Guohua Ji, Nan Wu and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Dongmei ZhangLaboratory of Medical Genetics, Harbin Medical University, Harbin, 150081, China.
Meiqi ZhaoLaboratory of Medical Genetics, Harbin Medical University, Harbin, 150081, China.
Ping JiangLaboratory of Medical Genetics, Harbin Medical University, Harbin, 150081, China.
Yunzhen ZhouLaboratory of Medical Genetics, Harbin Medical University, Harbin, 150081, China.
Xu YanLaboratory of Medical Genetics, Harbin Medical University, Harbin, 150081, China.
Chong ZhouLaboratory of Medical Genetics, Harbin Medical University, Harbin, 150081, China.
Yu MuLaboratory of Medical Genetics, Harbin Medical University, Harbin, 150081, China.
Shan XiaoLaboratory of Medical Genetics, Harbin Medical University, Harbin, 150081, China.
Guohua JiLaboratory of Medical Genetics, Harbin Medical University, Harbin, 150081, China.
Nan WuLaboratory of Medical Genetics, Harbin Medical University, Harbin, 150081, China.
Donglin SunLaboratory of Medical Genetics, Harbin Medical University, Harbin, 150081, China.
Xiaobo CuiLaboratory of Medical Genetics, Harbin Medical University, Harbin, 150081, China.
Shangwei NingCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Hongxue MengDepartment of Pathology, Harbin Medical University Cancer Hospital, Harbin, 150081, China.
Sheng XiaoDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Yan JinLaboratory of Medical Genetics, Harbin Medical University, Harbin, 150081, China. jinyan@hrbmu.edu.cn.

Funding

China Postdoctoral Science Foundation 2020T130159China Postdoctoral Science Foundation GZC20230649Department of Education, Heilongjiang Province LJGXCG2024-P12Heilongjiang Touyan Innovation Team Program Heilongjiang Touyan Innovation Team ProgramNational Natural Science Foundation of China 81802428National Natural Science Foundation of China 82172353Natural Science Foundation of Heilongjiang Province ZD2023H002Postdoctoral Research Foundation of China 2024MD753939
6 · The paper itself

Abstract

backgroundCervical cancer remains one of the leading causes of cancer-related deaths among women globally, and there is still a need to research molecular targets that can be used for prognosis assessment and personalized molecular therapies. Here, we investigate the role of potential molecular target ribosomal L22-like 1 (RPL22L1) on cervical cancer, identify its potential mechanisms, and explore its related applications in prognosis and molecular therapies.

methodsMultiple cervical cancer cohorts online, tissue microarrays and clinical tissue specimens were analyzed for the association between RPL22L1 expression and patient outcomes. Functional and molecular biology studies of cell and mice models were used to clarify the effects and potential mechanisms of RPL22L1 on cervical cancer.

resultsRPL22L1 is highly expressed in both cervical adenocarcinoma and squamous cell carcinoma, and its expression is significantly associated with histology grade, clinical stage, recurrence, vascular space involvement, tumor sizes and poor prognosis. In vitro and in vivo experiment revealed that RPL22L1 overexpression significantly promoted cervical cancer cell proliferation, migration, invasion, tumorigenicity and Sorafenib resistance, which were attenuated by RPL22L1 knockdown. Mechanistically, RPL22L1 competitively binds to ERK phosphatase DUSP6, leading to excessive activation of ERK. The combined application of ERK inhibitors can effectively inhibit RPL22L1 overexpressing cervical cancer cells both in vivo and in vitro.

conclusionRPL22L1 promotes malignant biological behavior of cervical cancer cells by competitively binding with DUSP6, thereby activating the ERK pathway. The combined use of Sorafenib and an ERK inhibitor is a potentially effective molecular targeted therapy for RPL22L1-high cervical cancer.

Indexed as

MAP Kinase Signaling SystemRibosomal ProteinsUterine Cervical NeoplasmsAnimalsCarcinogenesisCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMiceMice, Inbred BALB CMice, NudeMiddle AgedNeoplasm InvasivenessRibosomal ProteinsSorafenibCervical cancerERKRPL22L1Sorafenib

Identifiers

PMID40022129
PMCPMC11871735

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.